Open-label, Single-arm Phase 3B Implementation Study to Monitor the Effectiveness of the Single-dose Ad26.COV2.S COVID-19 Vaccine Among Health Care Workers in South Africa (VAC31518COV3012)
Latest Information Update: 08 Aug 2022
At a glance
- Drugs Ad26.COV2 S (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Acronyms Sisonke
- 16 Feb 2022 Status changed from recruiting to completed, according to Results presented at the 29th Conference on Retroviruses and Opportunistic Infections.
- 16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections.
- 09 Dec 2021 According to a Johnson & Johnson media release, the company announced the interim recommendation by the Strategic Advisory Group of Experts on Immunization (SAGE) for the World Health Organization (WHO) supporting the use of the Johnson & Johnson COVID-19 vaccine as a booster shot in persons aged 18 years and above, based on efficacy, safety and immunogenicity data from the company's trials and this study.